Antihyperglycemic therapy in adults with type 2 diabetes

Slides:



Advertisements
Similar presentations
 GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose  Type 2 diabetics little incretin effect  Reduced GLP-1 secretion.
Advertisements

Canadian Diabetes Association Clinical Practice Guidelines Weight Management in Diabetes Chapter 17 Sean Wharton, Arya M. Sharma, David C.W. Lau.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.
Diabetes in the 21 st Century 2010 Update. American Diabetes Association 2010 Guidelines – Diagnostic Criteria A1C > or = 6.5% is included as diagnostic.
PHARMACOLOGICAL THERAPY FOR TYPE 2 DIABETES Reyhane Azizi M.D Assistant Prof. of Endocrinology and Metabolism Shahid Sadoghi University of Medical Sciences.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
SGLT-2 Inhibitor with Incretins.
Supporting the Rationale for the Use of Dapagliflozin as an Add-on to Poorly Controlled Patients on Saxagliptin and Metformin Zachary Bloomgarden, MD Clinical.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
Taieb V, et al. Value Health Nov;18(7):A598.
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Copyright © 2015 by the American Osteopathic Association.
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Stuart A. Ross, MB CHB, FRACP, FRCP(C) 
Global Projections for Diabetes:
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence.
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
Clinical Application of New CV Outcomes Data
GLP-1 Receptor Agonists: How Early Is Appropriate?
A Deep Dive Into CVOTs.
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Case Study Role of DPP-4 Inhibitors
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Early and Intensive T2D Management:
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Continuous glucose monitoring tracings of two patients with type 1 diabetes (one patient per panel) on a day when aerobic exercise was performed (open.
LEADER One Year On.
RCHC’s Cardiovascular Health Initiative
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic Therapy
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
Approach to starting and adjusting insulin in type 2 diabetes.
Oral Combination Therapy for T2D
Management of Adult Patients with Hyperosmolar Hyperglycemic Syndrome
Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.
Patient Selection for Modern T2D Agents
Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.
Improving Overall Health
Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.
ADA/EASD general recommendations for type 2 diabetes management (1).
Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.
Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.
Glucose-lowering medication in type 2 diabetes: overall approach.
Multilevel Intervention Most scientific proof about developing health and health patronage.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Study design (A) and patient disposition (B).
ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,
Protocol for Management of Adult Patients with Diabetic Ketoacidosis
Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.
Algorithm for management of patients with pain due to DSPN
Renal licences of commonly used anti-diabetes drugs
Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation.
Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. Guideline approach to drug therapy in newly diagnosed type.
Glucose-lowering medication in type 2 diabetes: overall approach.
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Presentation transcript:

Antihyperglycemic therapy in adults with type 2 diabetes Antihyperglycemic therapy in adults with type 2 diabetes. *If patient does not tolerate or has contraindications to metformin, consider agents from another class in Table 8.1 of ref. 2. #GLP-1 receptor agonists and DPP-4 inhibitors should not be prescribed in combination. Antihyperglycemic therapy in adults with type 2 diabetes. *If patient does not tolerate or has contraindications to metformin, consider agents from another class in Table 8.1 of ref. 2. #GLP-1 receptor agonists and DPP-4 inhibitors should not be prescribed in combination. If a patient with ASCVD is not yet on an agent with evidence of cardiovascular risk reduction, consider adding. Reprinted with permission from the American Diabetes Association (2). Joshua J. Neumiller, and Guillermo E. Umpierrez Diabetes Spectr 2018;31:254-260 ©2018 by American Diabetes Association